Semaglutide vs Tirzepatide vs Retatrutide: Mechanisms

A plain-language comparison of the receptor mechanisms behind semaglutide, tirzepatide and retatrutide: GLP-1, GIP and glucagon signaling, and how their regulatory status differs.

Signal IQ Editorial5 min read · Updated Nov 8, 2026
Semaglutide vs Tirzepatide vs Retatrutide: Mechanisms
In this article
  1. The starting point: GLP-1
  2. Semaglutide: GLP-1 only
  3. Tirzepatide: GLP-1 plus GIP
  4. Retatrutide: adding the glucagon receptor
  5. Side-by-side comparison
  6. Receptor biology in a little more detail
  7. Reading trial news without hype
  8. Frequently asked questions
  9. References

Semaglutide, tirzepatide and retatrutide differ mainly in which receptors they activate. Semaglutide activates the GLP-1 receptor, tirzepatide activates the GLP-1 and GIP receptors, and retatrutide adds the glucagon receptor to those two. Semaglutide and tirzepatide are FDA-approved prescription medicines; retatrutide is investigational.

Key takeaways
  • The three drugs sit on a ladder of receptor targets: one (GLP-1), two (GLP-1 and GIP), or three (GLP-1, GIP and glucagon).
  • More receptors describes the design of the molecule; it does not guarantee a bigger or safer result for any one person.
  • Semaglutide and tirzepatide are used under FDA-approved labeling with defined indications, so details belong with a prescriber and the official label.
  • Retatrutide has been reported on in clinical trials but is not approved; online dosing information about it is not authoritative.

The starting point: GLP-1

Glucagon-like peptide-1 (GLP-1) is an incretin, a hormone released by the gut after meals. It helps coordinate several things at once: insulin release, suppression of glucagon, slower stomach emptying, and appetite signals in the brain. Medicines that switch on its receptor are called GLP-1 receptor agonists.

Native GLP-1 is broken down quickly by enzymes such as DPP-4. Engineered analogs are built to resist that breakdown and to act for longer, which is a large part of why they exist.

Semaglutide: GLP-1 only

Semaglutide is a GLP-1 receptor agonist engineered for longer action than the natural hormone. Its FDA-approved labeling includes indications such as type 2 diabetes and chronic weight management, depending on the specific product. The prescribing information for each product defines who it is for and what warnings apply, and that document is the right place to look rather than a general article.

Tirzepatide: GLP-1 plus GIP

Tirzepatide activates both the GLP-1 receptor and the receptor for glucose-dependent insulinotropic polypeptide (GIP). GIP is a second incretin that also influences insulin responses and metabolic signaling. The dual action is why tirzepatide is sometimes called a “twincretin.”

When reading about it, it helps to keep three things separate:

  1. The receptor profile, meaning what the molecule binds.
  2. Trial outcomes, meaning what studies measured, such as HbA1c, weight and cardiometabolic endpoints.
  3. Individual response, which varies and is best assessed under clinical supervision.

Trial results apply to the populations and conditions that were studied. They should not be extended to unsupervised use of compounded or gray-market products.

Retatrutide: adding the glucagon receptor

Retatrutide is described in the clinical literature as a triple agonist of the GLP-1, GIP and glucagon receptors. In normal physiology, glucagon raises blood glucose and also contributes to energy expenditure. Adding glucagon-receptor activity is a deliberate design choice built on hypotheses about thermogenesis and fat metabolism, and trials monitor for theoretical downsides such as effects on heart rate and glucose.

It remains investigational, so there is no approved label to consult. For a deeper walk through its pathways, see how retatrutide works, and for the research-protocol context see the retatrutide compound page.

Side-by-side comparison

MedicineReceptors activatedRegulatory status
SemaglutideGLP-1FDA-approved, defined indications
TirzepatideGLP-1 and GIPFDA-approved, defined indications
RetatrutideGLP-1, GIP and glucagonInvestigational

Mechanism does not predict an individual’s side-effect timeline. Plain-language pharmacology, such as half-life, is a more useful way to understand how long a drug acts; see the peptide half-life guide.

Receptor biology in a little more detail

GLP-1 receptors are G protein-coupled receptors found in pancreatic islet cells, the gastrointestinal tract, the heart, and brain regions that regulate appetite. GIP is co-secreted with GLP-1 after meals and affects insulin dynamics. Glucagon receptors raise glucose output from the liver but also feature in discussions of energy expenditure.

This vocabulary is useful for reading the “Mechanism of Action” sections of FDA labels and for interpreting trial abstracts without being lost in jargon. It is not a guide to what to use.

Note: Semaglutide and tirzepatide are prescription medicines, and their use belongs under the supervision of a licensed clinician and the official labeling. This article gives no dosing for any of the three. Retatrutide is investigational and not approved for human use; internet dosing and conversion charts between these drugs are not reliable.

Reading trial news without hype

  • Check the population studied, such as obesity with comorbidities or diabetes.
  • Check the endpoint, for example percent weight change versus placebo, not before-and-after photos.
  • Check the duration and the discontinuation rate.
  • Check the regulatory status: approved or investigational.

Peer-reviewed trial reports are indexed on PubMed, and FDA labels list approved claims. For a quality check on any product labeled as a peptide, learn to read a certificate of analysis with how to read a peptide CoA, and read about the regulatory divide in research use vs human use.

Compounded or gray-market products raise a further problem: a label does not verify the contents, and compounded versions can differ from approved products in salt form, concentration and oversight. Other compounds that act on metabolism are catalogued under peptides by goal and in the Signal Library, including MOTS-c, for which human evidence in combination with these drugs is not established. Questions can also go to Pulse.

Frequently asked questions

Is tirzepatide stronger because it hits two receptors?

Dual agonism explains the design, not a guaranteed result. Outcomes depend on the endpoints trials measured and on each person’s supervised care.

Does retatrutide’s glucagon activity automatically burn fat?

No. Glucagon-receptor activity is part of a research hypothesis that trials monitor, not a promise of results outside clinical evidence.

Can I switch between semaglutide and tirzepatide with an online conversion chart?

Not safely. Switching should be done only under clinician supervision with approved or lawfully compounded products, not forum conversions.

Are compounded GLP-1 products identical to FDA-approved pens?

They may differ in salt form, concentration, additives and quality oversight. A licensed prescriber and pharmacist can explain the risks.

Is retatrutide FDA-approved?

No. It is investigational, and trial publications rather than product labels are the source of reliable information.

Why learn the mechanisms at all?

Understanding receptors helps you interpret reported side effects, read official labels, and ask better questions of a clinician.

References

  1. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial, N Engl J Med, 2023 — pubmed.ncbi.nlm.nih.gov
  2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), N Engl J Med, 2022 — pubmed.ncbi.nlm.nih.gov

Go deeper on Signal IQ

Dosing & protocolRetatrutide

Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.

Ask Pulse

Educational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.

Keep reading